



---

Open Access Journal by MDPI

---

Impact Factor 2.5

CiteScore 3.1

Indexed in PubMed

# Epigenomes



[mdpi.com/  
journal/  
epigenomes](https://mdpi.com/journal/epigenomes)



# Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior. *Epigenomes* is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

---

## **Editor-in-Chief**

Prof. Dr. Ernesto Guccione

---

## **Associate Editor**

Dr. Che-Kun James Shen

---

## **Aims**

*Epigenomes* (ISSN 2075-4655) is an open access journal which provides an advanced forum for research studies on Epigenetics and Epigenomics. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible.

---

## Scope

- Functional studies dealing with identification/modus operandi/structure–function relationships or biological activity of methylases, demethylases, acetylases, methyl-binding proteins, or any other type of enzymes involved in DNA, RNA or histone modifications;
- Studies reporting genome-wide epigenetic status of cells or tissues in specific biologically relevant contexts;
- Studies describing insights into the role of epigenetics and epitranscriptomics in physical diseases (e.g., cancer, premature aging, allergy, obesity) and psychopathologies (e.g., schizophrenia, autism, addiction);
- Studies describing the effect of environmental changes on the epigenetic or epitranscriptomic status of cells or tissues;
- Studies describing the inheritance or fixation of epigenetic characteristics;
- Description of novel methods to study DNA methylation, histone methylation, RNA modifications, histone acetylation or other types of epigenetic and/or epitranscriptomic modifications in a global fashion;
- Studies describing novel tools and technologies for epigenetic or epitranscriptomic studies and therapeutics.

---

## Author Benefits

### Open Access

Unlimited and free access for readers

### No Copyright Constraints

Retain copyright of your work and free use of your article

### Thorough Peer-Review

### No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

### Coverage by Leading Indexing Services

Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPlus / SciFinder, and other databases

### Rapid Publication

A first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2023)

MDPI is a member of

CASPA



STM<sup>1</sup>



SPARC\*  
Europe



DOAJ



ORCID

### Affiliated Society

Epigenetics Society (ES)



### Editorial Office

[epigenomes@mdpi.com](mailto:epigenomes@mdpi.com)

MDPI

St. Alban-Anlage 66

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[mdpi.com](http://mdpi.com)

